Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17

Abstract

This study investigates the potential clinical significance of c-erbB-2 gene and chromosome 17 alterations by fluorescence in situ hybridization (FISH) analysis and HER2/neu overexpression by immunohistochemical staining in transitional cell carcinoma (TCC) of urinary bladder correlating the results with tumor stage and grade categories and with clinical behavior. Sixty-three cases of TCC retrieved from the files of 2 institutions were analyzed for chromosome 17 aberrations and c-erbB-2 amplification by FISH analysis and evaluated immunohistochemically for HER2/neu overexpression. Five tumors were G1, 29 intermediate grade (G2), and 29 tumors high grade (G3); 32 tumors had stage Ta, 18 tumors T1, and 13 tumors T2. We found polysomy of chromosome 17 in 58.7% of TCC with average chromosome copy number >2.26; increased number of HER2/neu gene copy was observed in 66.7% of tumors. C-erbB-2 amplification occurred in 6.3% of tumors. Immunohistochemically, 60.3% of TCC overexpressed HER2/neu and 39.7% of tumors were negative. All tumors with polysomy showed simultaneously increase of HER2/neu gene copy number of which 34/37 with protein overexpression. A statistically significant correlation between polysomy of chromosome 17 and tumor stage (P = .0003) and tumor grade (P < .0001) was found; polysomy was not seen in G1 tumors; however, 8/29 G2 tumors and 29/29 G3 tumors revealed polysomy of chromosome 17; in 8/32 Ta tumors, 14/18 T1 and 13/13 of deeply invasive tumors (T2) polysomy 17 was observed. Moreover, it was found that 7 superficial tumors (1 Ta and 6 T1) showed high polysomy with average of chromosome 17 copy number ≥3.76 as observed in all invasive tumors. The data suggest that although HER2/neu amplification, found in high grade and invasive tumors, is a rare event in TCC, polysomy of chromosome 17 is an important factor correlated with tumor stage and grade categories and could be considered a molecular marker of tumor progression with interesting diagnostic implications.

Keywords

chromosome 17 FISH analysis HER2 neu polysomy transitional cell carcinoma

Get full access to this article

View all access options for this article.

References

Baffa R. , Letko J. , McClung C. , LeNoir J. , Vecchione A. , Gomella LG Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res. 2006;25:145-160.

Fradet Y. , Lacombe L. Can biological markers predict recurrence and progression of superficial bladder cancer? Curr Opin Urol. 2000;10:41-45.

Hauser-Kronberger C. , Peham K. , Grall J. , Rausch W. , Hutarew G. , Dietze O. Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder. J Urol. 2006;175:875-880.

Sauter G. , Moch H. , Moore D. , et al. Heterogeneity of erbB-2 gene amplification in bladder cancer . Cancer Res. 1993;53:2199-2203.

Langner C. , Gross C. , Rehak P. , Ratschek M. , Rüschoff J. , Zigeuner R. HER2/neu protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique. Urology. 2005;65:176-180.

Olayioye MA , Beuvink I. , Horsch K. , Daly JM , Hynes NE ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem. 1999 ;274:17209-17218.

Olayioye MA , Neve RM , Lane HA , Hynes NE The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19: 3159-3167.

Giltnane JM , Murren JR , Rimm DL , King BL AQUA and FISH analysis of IHC expression and amplification in a small cell lung carcinoma tissue microarray. Histopathology. 2006;49:161-169.

Kanta SY , Yamane T. , Dobashi Y. , Mitsui F. , Kono K. , Ooi A. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2/neu gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol. 2006;37:1333-1343.

10.

Shiga H. , Rasmussen AA , Johnston PG , et al. Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer. Head Neck. 2000;22:599-608.

11.

Gullick WJ The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer Suppl. 1990 ;5:55-61.

12.

Jemal A. , Siegel R. , Ward E. , et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.

13.

Thrasher JB , Crawford ED Current management of invasive and metastatic transitional cell carcinoma of the bladder. J Urol. 1993;149:957-972.

14.

Trkova M. , Babjuk M. , Duskova J. , et al. Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer. Cancer Lett. 2006;242:68-76.

15.

Edwards J. , Duncan P. , Going JJ , Grigor KM , Watters AD , Bartlett JM Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder. Br J Cancer. 2001;85:1894-1899.

16.

Watters AD , Ballantyne SA , Going JJ , Grigor KM , Bartlett JM Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder. BJU Int. 2000;85:42-47.

17.

Watters AD , Going JJ , Cooke TG , Bartlett JM Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 2003;77:109-114.

18.

Watters AD , Going JJ , Grigor KM , Bartlett JM Progression to detrusor-muscle invasion in bladder carcinoma is associated with polysomy of chromosomes 1 and 8 in recurrent pTa/pT1 tumours. Eur J Cancer. 2002;38:1593-1599.

19.

Latif Z. , Watters AD , Dunn I. , Grigor K. , Underwood MA , Bartlett JM HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2/neu therapy? Eur J Cancer. 2004;40:56-63.

20.

Latif Z. , Watters AD , Dunn I. , Grigor KM , Underwood MA , Bartlett JM HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer. 2003;89:1305-1309.

21.

Ohta JI , Miyoshi Y. , Uemura H. , et al. Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clin Cancer Res. 2001;7:2463-2467.

22.

Wang S. , Hossein Saboorian M. , Frenkel EP , et al. Aneusomy 17 in breast cancer: its role in IHC protein expression and implication for clinical assessment of IHC status. Mod Pathol. 2002;15:137-145.

23.

Gullo G. , Bettio D. , Torri V. , Masci G. , Salvini P. , Santoro A. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2/neu-positive metastatic breast cancer [published online ahead of print July 29, 2008]. Invest New Drugs. doi:10.1007/s10637-008-9155-y.

24.

Matsubara H. , Yamada Y. , Naruse K. , et al. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol Rep. 2008;19:57-63.

25.

Zhau HE , Zhang X. , von Eschenbach AC , et al. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog. 1990 ;3:254-257.

26.

Mellon JK , Lunec J. , Wright C. , Horne CH , Kelly P. , Neal DE C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol. 1996;155:321-326.

27.

Underwood M. , Bartlett J. , Reeves J. , Gardiner DS , Scott R. , Cooke T. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res. 1995 ;55:2422-2430.

28.

Caner V. , Turk NS , Duzcan F. , et al. No strong association between IHC protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res. 2008;14:261-266.

29.

Shiga K. , Shiga C. , Sasano H. , et al. Expression of c-erbB-2 in human esophageal carcinoma cells: overexpression correlated with gene amplification or with GATA-3 transcription factor expression. Anticancer Res. 1993;13:1293-1301.

30.

Hollywood DP , Hurst HC Targeting gene transcription: a new strategy to down-regulate c-erbB-2 expression in mammary carcinoma. Br J Cancer. 1995;71:753-757.

31.

Ribal MJ , Alcaraz A. , Mengual L. , et al. Chromosomal high-polysomies predict tumour progression in T1 transitional cell carcinoma of the bladder. Eur Urol. 2004;45:593-599.

32.

Krüger S. , Mess F. , Böhle A. , Feller AC Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol. 2003;23:41-48.

33.

Leonardo C. , Merola R. , Orlandi G. , Leonardo F. , Rondoni M. , De Nunzio C. C-erb-2 gene amplification and chromosomal anomalies in bladder cancer: preliminary results. J Exp Clin Cancer Res. 2005;24:633-638.